fluoxetine has been researched along with Myasthenic Syndromes, Congenital in 13 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Myasthenic Syndromes, Congenital: A heterogeneous group of disorders characterized by a congenital defect in neuromuscular transmission at the NEUROMUSCULAR JUNCTION. This includes presynaptic, synaptic, and postsynaptic disorders (that are not of autoimmune origin). The majority of these diseases are caused by mutations of various subunits of the nicotinic acetylcholine receptor (RECEPTORS, NICOTINIC) on the postsynaptic surface of the junction. (From Arch Neurol 1999 Feb;56(2):163-7)
| Excerpt | Relevance | Reference |
|---|---|---|
| "DOK7 congenital myasthenic syndrome (DOK7-CMS) generally presents early in life and is treated with salbutamol or ephedrine." | 5.48 | DOK7 myasthenic syndrome with subacute adult onset during pregnancy and partial response to fluoxetine. ( Basto, JP; Cruz, S; Peres, J; Salgado, V; Santos, L; Santos, M; Tavares, P; Valverde, AH, 2018) |
| "The slow-channel congenital myasthenic syndrome is an autosomal dominant neuromuscular disorder caused by mutations in different subunits of the acetylcholine receptor." | 1.72 | Treatment of slow-channel congenital myasthenic syndrome in a Thai family with fluoxetine. ( Dejthevaporn, C; Engel, AG; Pulkes, T; Rattanasiri, S; Wetchaphanphesat, S; Witoonpanich, R, 2022) |
| "Congenital myasthenic syndromes are rare hereditary disorders caused by mutations associated with proteins of the neuromuscular junction." | 1.62 | Rare slow channel congenital myasthenic syndromes without repetitive compound muscle action potential and dramatic response to low dose fluoxetine. ( Ceylaner, S; Deymeer, F; Durmus, H; Hashemolhosseini, S; Sticht, H, 2021) |
| "Treatment with fluoxetine resulted in remarkable improvement and regain of muscle power and independence from assisted ventilation." | 1.62 | A rare mutation in the COLQ gene causing congenital myasthenic syndrome with remarkable improvement to fluoxetine: A case report. ( Beeson, D; Chang, T; Cossins, J; Fernando, A; Gooneratne, IK; Gunaratne, K; Maxwell, S; Nandasiri, S; Vidanagamage, A, 2021) |
| "DOK7 congenital myasthenic syndrome (DOK7-CMS) generally presents early in life and is treated with salbutamol or ephedrine." | 1.48 | DOK7 myasthenic syndrome with subacute adult onset during pregnancy and partial response to fluoxetine. ( Basto, JP; Cruz, S; Peres, J; Salgado, V; Santos, L; Santos, M; Tavares, P; Valverde, AH, 2018) |
| "Fluoxetine is a selective serotonin reuptake inhibitor and long-lived open channel blocker of the acetylcholine receptor, often used in the treatment of slow-channel congenital myasthenic syndromes (CMS)." | 1.46 | Rapsyn congenital myasthenic syndrome worsened by fluoxetine. ( Benarroch, EE; Laughlin, RS; Litchy, WJ; Milone, M; Visser, AC, 2017) |
| "The slow-channel congenital myasthenic syndrome (SCS) is an inherited neurodegenerative disease that caused mutations in the acetylcholine receptor (AChR) affecting neuromuscular transmission." | 1.42 | Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome. ( Alicea-Vázquez, V; Báez-Pagán, CA; Gomez, CM; Grajales-Reyes, GE; Grajales-Reyes, JG; Lasalde-Dominicci, JA; Pytel, P; Robinson, K; Zhu, H, 2015) |
| "Fluoxetine is an open channel blocker of fetal muscle acetylcholine (ACh) receptor (AChR) and slow-channel mutant AChRs." | 1.40 | Fluoxetine prevents acetylcholine-induced excitotoxicity blocking human endplate acetylcholine receptor. ( Catalano, M; Deflorio, C; Fucile, S; Grassi, F; Limatola, C, 2014) |
| "Slow channel congenital myasthenic syndrome is a dominant disorder characterized by prolonged acetylcholine receptor ion-channel activation." | 1.39 | Slow channel congenital myasthenic syndrome responsive to a combination of fluoxetine and salbutamol. ( Beeson, D; Finlayson, S; Howard, R; Kullmann, DM; Palace, J; Spillane, J; Webster, R, 2013) |
| "Slow-channel congenital myasthenic syndrome (CMS) is a rare subtype of CMS caused by dominant "gain of function" mutations in the acetylcholine receptor." | 1.38 | A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome. ( Abicht, A; Argov, Z; Chaouch, A; Colomer, J; Dusl, M; Guergueltcheva, V; Lindberg, C; Lochmüller, H; Muelas, N; Müller, JS; Nascimento, A; Rakocević-Stojanović, V; Schara, U; Scola, RH; Vilchez, JJ; Werneck, LC, 2012) |
| "Fluoxetine therapy was started and gradually increased over 2 months." | 1.33 | Long-term improvement of slow-channel congenital myasthenic syndrome with fluoxetine. ( Abicht, A; Colomer, J; Gonzalez, V; Lochmüller, H; Müller, JS; Nascimento, A; Pons, M; Vernet, A, 2006) |
| "The slow-channel syndrome is one of the congenital myasthenic syndromes attributed to inherited kinetic disorders of the ion channel of the acetylcholine receptor of the neuromuscular junction." | 1.33 | [Neurophysiological study in slow-channel congenital myasthenic syndrome: case report]. ( Arruda, WO; Kay, CS; Lorenzoni, PJ; Scola, RH; Werneck, LC, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Dejthevaporn, C | 1 |
| Wetchaphanphesat, S | 1 |
| Pulkes, T | 1 |
| Rattanasiri, S | 1 |
| Engel, AG | 2 |
| Witoonpanich, R | 1 |
| Durmus, H | 1 |
| Sticht, H | 1 |
| Ceylaner, S | 1 |
| Hashemolhosseini, S | 1 |
| Deymeer, F | 1 |
| Vidanagamage, A | 1 |
| Gooneratne, IK | 1 |
| Nandasiri, S | 1 |
| Gunaratne, K | 1 |
| Fernando, A | 1 |
| Maxwell, S | 1 |
| Cossins, J | 1 |
| Beeson, D | 3 |
| Chang, T | 1 |
| Lee, M | 1 |
| Palace, J | 2 |
| Santos, M | 1 |
| Cruz, S | 1 |
| Peres, J | 1 |
| Santos, L | 1 |
| Tavares, P | 1 |
| Basto, JP | 1 |
| Salgado, V | 1 |
| Valverde, AH | 1 |
| Deflorio, C | 1 |
| Catalano, M | 1 |
| Fucile, S | 1 |
| Limatola, C | 1 |
| Grassi, F | 1 |
| Zhu, H | 1 |
| Grajales-Reyes, GE | 1 |
| Alicea-Vázquez, V | 1 |
| Grajales-Reyes, JG | 1 |
| Robinson, K | 1 |
| Pytel, P | 1 |
| Báez-Pagán, CA | 1 |
| Lasalde-Dominicci, JA | 1 |
| Gomez, CM | 1 |
| Visser, AC | 1 |
| Laughlin, RS | 1 |
| Litchy, WJ | 1 |
| Benarroch, EE | 1 |
| Milone, M | 1 |
| Chaouch, A | 1 |
| Müller, JS | 2 |
| Guergueltcheva, V | 1 |
| Dusl, M | 1 |
| Schara, U | 1 |
| Rakocević-Stojanović, V | 1 |
| Lindberg, C | 1 |
| Scola, RH | 2 |
| Werneck, LC | 2 |
| Colomer, J | 2 |
| Nascimento, A | 2 |
| Vilchez, JJ | 1 |
| Muelas, N | 1 |
| Argov, Z | 1 |
| Abicht, A | 2 |
| Lochmüller, H | 2 |
| Finlayson, S | 1 |
| Spillane, J | 1 |
| Kullmann, DM | 1 |
| Howard, R | 1 |
| Webster, R | 1 |
| Harper, CM | 1 |
| Fukodome, T | 1 |
| Vernet, A | 1 |
| Pons, M | 1 |
| Gonzalez, V | 1 |
| Lorenzoni, PJ | 1 |
| Kay, CS | 1 |
| Arruda, WO | 1 |
1 review available for fluoxetine and Myasthenic Syndromes, Congenital
| Article | Year |
|---|---|
Therapeutic strategies for congenital myasthenic syndromes.
Topics: Adrenergic beta-Agonists; Breast Feeding; Cholinergic Antagonists; Cholinesterase Inhibitors; Female | 2018 |
12 other studies available for fluoxetine and Myasthenic Syndromes, Congenital
| Article | Year |
|---|---|
Treatment of slow-channel congenital myasthenic syndrome in a Thai family with fluoxetine.
Topics: Fluoxetine; Humans; Mutation; Myasthenic Syndromes, Congenital; Prospective Studies; Receptors, Chol | 2022 |
Rare slow channel congenital myasthenic syndromes without repetitive compound muscle action potential and dramatic response to low dose fluoxetine.
Topics: Action Potentials; Adult; Amino Acid Sequence; Dose-Response Relationship, Drug; Fluoxetine; Humans; | 2021 |
A rare mutation in the COLQ gene causing congenital myasthenic syndrome with remarkable improvement to fluoxetine: A case report.
Topics: Acetylcholinesterase; Asian People; Collagen; Fluoxetine; Humans; Male; Middle Aged; Muscle Proteins | 2021 |
DOK7 myasthenic syndrome with subacute adult onset during pregnancy and partial response to fluoxetine.
Topics: Adult; Female; Fluoxetine; Humans; Muscle Proteins; Muscle Weakness; Myasthenic Syndromes, Congenita | 2018 |
Fluoxetine prevents acetylcholine-induced excitotoxicity blocking human endplate acetylcholine receptor.
Topics: Acetylcholine; Cell Death; Cell Survival; Cells, Cultured; Fluoxetine; HEK293 Cells; Humans; In Vitr | 2014 |
Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome.
Topics: Animals; Disease Models, Animal; Fluoxetine; Male; Mice; Mice, Transgenic; Motor Activity; Myastheni | 2015 |
Rapsyn congenital myasthenic syndrome worsened by fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Female; Fluoxetine; Humans; Muscle Proteins; Mutati | 2017 |
A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome.
Topics: Adolescent; Adult; Aged; Cholinesterase Inhibitors; Female; Fluoxetine; Follow-Up Studies; Humans; M | 2012 |
Slow channel congenital myasthenic syndrome responsive to a combination of fluoxetine and salbutamol.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Drug Therapy, Combination; Fluoxetine; Humans; Male; | 2013 |
Treatment of slow-channel congenital myasthenic syndrome with fluoxetine.
Topics: Adult; Cholinergic Antagonists; Drug Evaluation; Drug Hypersensitivity; Female; Fluoxetine; Genes, D | 2003 |
Long-term improvement of slow-channel congenital myasthenic syndrome with fluoxetine.
Topics: Adolescent; Cholinesterase Inhibitors; DNA Mutational Analysis; Dose-Response Relationship, Drug; Dr | 2006 |
[Neurophysiological study in slow-channel congenital myasthenic syndrome: case report].
Topics: Action Potentials; Adult; Electric Stimulation; Electromyography; Electrophysiology; Fluoxetine; Hum | 2006 |